

ASX Announcement

1 October 2020

Notice of Acceptance received for Regeneus' Australian patent application covering use of biomarkers to monitor disease progression for stem cell therapy

- Accepted Australian patent application covers the use of biomarkers to monitor disease progression in patients undergoing mesenchymal cell (MSC) therapies for inflammatory conditions
- Provides coverage for a broad range of MSC therapeutics for inflammatory conditions in combination with biomarkers
- Allows Regeneus to monitor inflammatory diseases and conditions which will allow clinicians to better guide patient treatment

Regeneus Ltd (ASX: RGS) (Regeneus or the Company), a clinical-stage regenerative medicine company, today announces that it has received a Notice of Acceptance for its Australian patent application, covering the use of biomarkers to monitor disease progression in patients undergoing mesenchymal stem cell (MSC) therapy for inflammatory conditions.

Biomarkers are useful for clinicians to monitor the progression of diseases and medical conditions, and help guide and determine treatment options for patients. For inflammatory conditions such as osteoarthritis, biomarkers can be used to measure the effects of MSC therapies and can be analysed via a patient's blood or other body fluids.

Well-recognised biomarkers for inflammatory conditions include MIF (Macrophage Migration Inhibitory Factor), COMP (Cartilage oligomeric matrix protein) and CTX-II (Crosslinked C-telopeptides of type II collagen). MIF is a key modulator in promoting and modulating the magnitude of the inflammatory response, while COMP and CTX-II are degradation products of joint tissues as joint tissues degrade, COMP and CTX-II increase/decrease.

Regeneus' patent will cover use of the above biomarkers to monitor inflammatory conditions in patients undergoing a broad range of MSC therapies.

As osteoarthritis is characterised by the progressive loss of articular cartilage, this patent allows Regeneus to monitor the above biomarkers to measure severity of a patient's disease, determine if, and when, further treatments may be required, and help better manage the disease before it worsens.

The grant of this Australian patent expected in January 2021 will further strengthen and compliment Regeneus' existing intellectual property (IP); the Company's other patents

are mostly directly related to its platform technologies (Progenza™ and Sygenus), while this patent facilitates the monitoring of inflammatory conditions.

Regeneus has corresponding patents granted in Japan. The Australian patent to be granted patent will have an expiry date in 2034.

-ENDS-

About Regeneus

Regeneus Ltd (ASX:RGS) is a Sydney-based clinical-stage regenerative medicine company using stem cell technologies to develop a portfolio of novel cell-based therapies to address unmet medical needs in human health markets with a focus on neuropathic pain, including osteoarthritis and various skin conditions, with its platform technologies Progenza and Sygenus. Visit www.regeneus.com.au for more information.

Authorisation & Additional information

This announcement was authorised by the Board of Directors of Regeneus Ltd

Investor and Media Contact

WE Communications

T: 02 9237 2805

E: WE-AURegeneus@we-worldwide.com